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Abstract: Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies 
characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various 
clinical features. Patients with MDS, in particular those with intermediate-2 (Int-2) and high-risk 
disease, have a poor prognosis. The mainstay of treatment includes cytoxic chemotherapy and 
supportive care. Over the last decade, promising results from studies focusing on hypomethylat-
ing agents, such as decitabine (5-aza-deoxycytidine) and 5-azacitidine, have led to the expansion 
of the therapeutic arsenal for MDS. This review presents the current data available on the clinical 
efficacy and safety profile for decitabine as a treatment for MDS. Although not fully understood, 
decitabine’s antitumor activity may involve its ability to induce hypomethylation and reactivation 
of genes responsible for cellular differentiation, stimulate an immune response, induce DNA 
damage/apoptotic response pathways, and/or augment stem cell renewal. Future studies that use 
epigenetic therapies that combine hypomethylating agents with histone deacetylase inhibitors 
(HDACi) and head-to-head comparison studies of decitabine and 5-azacitidine will provide 
valuable pre-clinical and clinical data, enhancing our understanding of these drugs.
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Introduction
Myelodysplastic syndromes (MDS) are classified as one of the five major categories 
of myeloid neoplasms according to the 2008 World Health Organization (WHO) 
classification system.1 MDS is a heterogeneous group of clonal stem cell disorders, 
which often feature a hypercellular bone marrow, peripheral cytopenias, and dysplasia 
in both peripheral blood and bone marrow. For the diagnosis of MDS, the minimal 
morphologic criteria include the identification of dysplasia in at least 10% of cells of 
any of the myeloid lineages in the peripheral blood/bone marrow after exclusion of 
acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML).2 
MDS is chronic in most cases with the potential for worsened cytopenias over time 
due to bone marrow failure and progression to AML. More than 10,000 cases of MDS 
are diagnosed annually in the United States, with a median age of 71 years old.3
The International Prognostic Scoring System (IPSS) has been used as a clinical pre-
dictor of progression to AML.4 The IPSS uses three criteria to evaluate risk, including 
the percentage of blasts in the marrow, chromosomal abnormalities, and the number 
of cytopenias. Based on these criteria, a score of low-risk MDS, intermediate-1 (Int-1) 
risk, intermediate-2 (Int-2) risk, and high-risk MDS is assigned. Lower risk disease 
generally includes patients diagnosed with the WHO subtypes of refractory anemia, 
refractory anemia with ringed sideroblasts, refractory cytopenias with multilineage OncoTargets and Therapy 2010:3 
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dysplasia, MDS with del(5q), unclassifiable MDS, and 
patients assigned to IPSS low-risk and Int-1. Higher risk 
MDS includes patients with refractory anemia with excess 
blasts, and patients assigned to IPSS Int-2 and higher. Patients 
with MDS in general have a poor prognosis, with 3-year 
survival rates at a dismal 35%.3 In particular, those with 
higher-risk MDS have a survival rate of 0.4 to 1.2 years and 
a high risk for progression to AML.5
Currently, there is no consensus for treating patients 
with higher-risk MDS. Prior to the widespread use of the 
hypomethylating agents, decitabine (5-aza-2′-deoxycytidine) 
and 5-azacitidine, cytotoxic therapy or supportive care were 
the traditional mainstays of therapy. Supportive care offered 
to patients with MDS includes blood transfusions, admin-
istration of hematopoietic growth factors, and antibiotics 
for prophylaxis or treatment of opportunistic infections. 
Unfortunately, patients receiving these therapies often die 
of complications of cytopenias, progressive disease, and/or 
iron overload. Hematopoietic cell transplantation (HCT) is 
the only potentially curative therapy available. However, 
because the vast majority of MDS patients are over the age 
of 65 years with co-morbidities, intensive treatment options, 
such as induction chemotherapy and allogeneic HCT, are not 
feasible for many patients.
In the last two decades, the use of epigenetic therapy, 
such as decitabine, has gained popularity, given its favorable 
side effect profile and its potential to improve survival.6,7 
Decitabine was approved by the US Food and Drug Admin-
istration (FDA) in 2006 for the treatment of de novo and 
secondary MDS (treatment-related MDS, t-MDS).8 Here 
we present a review of the clinical efficacy and safety of 
decitabine in the treatment of MDS with an explicit focus 
on the clinical trials published since Kantarjian et al’s multi-
institutional, Phase III randomized study comparing clinical 
outcomes after treatment with decitabine versus best sup-
portive care for patients diagnosed with MDS (Table 1).9
Pharmacology of decitabine
Decitabine contains deoxyribose as its sugar base and is 
incorporated into DNA (Figure 1A). The drug is considered 
to be chemically unstable when in basic or acidic solutions, 
but at neutral pH, it has a half-life of 7 days at 4°C, 96 hours 
at 20°C, and 21 hours at 37°C.10,11 Once inside the cell, 
decitabine needs to be activated to 5-aza-2′-deoxycytidine-
5′-triphosphate. The rate-limiting step in this process is 
the conversion of decitabine to 5-aza-2′-deoxycytidine-
5′-monophosphate, a reaction catalyzed by deoxycytidine 
kinase. Subsequent phosphorylation events yield the 
triphosphate form, which can be incorporated at positions 
in DNA that normally contain cytidine.
5-azacitidine is chemically related to decitabine. It 
contains a ribose sugar ring, and as such, is incorporated 
largely into RNA and at a lower frequency into DNA. Once 
incorporated into DNA, its mode of action is thought to be 
similar to decitabine.
Only cytosine (or 5-azacitidine, azaC) residues followed 
by guanines are substrates for DNA methylation in somatic 
cells. Once the DNA methyltransferase enzymes (DNMT) 
recognize an azaC-G dinucleotide, they become trapped 
covalently to the cytosine residue, since the enzymes are 
unable to complete the enzymatic reaction due to the nitrogen 
at the 5-position (Figure 1B). Once covalently attached 
to the DNA, the mechanisms by which azaC mediates 
hypomethylation are not yet entirely clear. A widely held 
model postulates that trapped DNMT enzymes result in 
enzyme degradation, lower DNMT levels, and ultimately, 
hypomethylation.
The clinical activity of decitabine and its demethylating 
activity are not fully understood. Hypotheses regarding how 
hypomethylation and/or changes to chromatin structure result 
in clinical remissions include: reversal of cancer-associated 
hypermethylation events, induction of cellular differentia-
tion, effects on stem cell populations, changes in the rate of 
apoptosis, induction of an immune response, and/or induc-
tion of DNA damage response pathways.12 Therefore, the 
hypomethylating drugs lower DNA methylation levels and 
alter chromatin structure, and much research still remains to 
be done to elucidate the molecular mechanism underlying 
clinical remissions.
DNA methylation and histone modification are both 
examples of potentially reversible epigenetic changes that 
can alter gene expression patterns. One mechanism of epi-
genetic gene silencing that is not fully understood includes 
hypermethylation of DNA sequences called CpG islands, 
which contain a high concentration of CpG dinucleotides 
and often overlap gene promoters. Methylated CpG islands 
bind specific proteins to recruit transcriptional corepressors 
such as histone deacetylases (HDACs). Removal of the acetyl 
groups by HDACs from the lysine tails of the histones leads 
to gene silencing. Thus, both DNA methylation and histone 
deacetylation are associated with gene silencing, providing a 
rationale for the combining a hypomethylating agent with a 
histone deacetylase inhibitor in order to induce clinical remis-
sions, by re-activating gene expression, at least in theory.
Several clinical trials using decitabine, or more exten-
sively 5-azacitidine, have incorporated correlative studies to OncoTargets and Therapy 2010:3 
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try to assess the biochemical effects of these drugs in patients. 
In two Phase I studies that tested a hypomethylating agent in 
combination with a histone deacetylase inhibitor (HDACi), 
although treatment with a hypomethylating agent resulted in 
increased levels of acetylated histones, there was no further 
increase after treatment with the HDACi.13,14 Therefore, there 
is little evidence currently that the hypomethylating agents are 
synergistic with HDACis as theorized. In another Phase I trial 
of 5-azacitidine combined with entinostat, another HDACi, 
bone marrow cells were tested for DNA methylation across 
14,000 promoter regions using a microarray based assay, and 
DNA hypomethylation was present by day 15 and persisted 
to day 29, with DNA hypomethylation occurring across all 
chromosomal regions, often in areas containing SINE/Alu 
repetitive elements.15
Clinical efficacy as first-line  
therapy for MDS
In the past, the heterogeneic clinical/pathologic features and 
cytogenetic abnormalities of MDS presented a challenge to 
consistent outcome evaluation after treatment. To address this 
problem, an International Working Group (IWG) of investiga-
tors established response criteria in myelodysplasia in 2000.16 
The IWG response criteria have been adopted widely, and 
hence, provide clinicians with a useful standardized tool to 
measure the efficacy of decitabine, for instance, in the treat-
ment of MDS. Complete remission (CR) in the bone mar-
row is defined as fewer than 5% blasts in the bone marrow 
without evidence of dysplasia, and in the peripheral blood is 
defined as: neutrophils of 1500/mm3 or more, a hemoglobin 
greater than 11 g/dL, platelets of 100,000/mm3 or more, 
absence of blasts, and no dysplasia for at least 8 weeks. To 
achieve partial remission (PR), CR criteria must be met if 
abnormal prior to therapy, except that bone marrow blasts 
must decrease by 50% or more compared to pretreatment 
levels for at least 8 weeks. Cytogenetic response is divided 
into two categories: major, for responses in which there is no 
detectable cytogenetic abnormality, and minor, for responses 
in which there is 50% or more reduction in the number of 
abnormal metaphases. Hematologic improvement (HI) of 
at least 8 weeks is defined by major and minor categories. 
Major HI includes a 100% increase in the neutrophil count, 
or an increase of at least 500/µL if the baseline neutrophil 
count was less than 1500/µL; transfusion independence, or 
an increase of at least 2 g/dL in hemoglobin level; and for 
platelets, it is defined as transfusion independence, or an 
increase of 30,000/µL, if the baseline platelet count was 
less than 100,000/µL. Modifications of the IWG response 
criteria in 2006 included, among others: consolidating major 
and minor HI into clinically relevant HI, changing duration 
of CR or PR to a minimum of 4 weeks instead of 8 weeks, 
permitting persistent dysplasia in CR, including marrow CR 
(mCR) without recovery of counts as a new category, and 
defining of AML as at least 20% or more blasts by WHO 
classification.17 These criteria have been adopted in the stud-
ies described below, and they allow for comparisons across 
the clinical trials.
Decitabine was initially studied as a cytotoxic agent at 
doses of 1500–2500 mg/m2 per course. This led to delayed 
and prolonged myelosuppression despite demonstrating 
activity in leukemias.18–20 In contrast to high doses where 
decitabine has cytotoxic effects, selective DNA demethyl-
ating activity was seen at much lower doses, around 100 
to150 mg/m2 per course.8 Zagonel et al studied two low-dose 
schedules of decitabine (45 to 50 mg/m2/day for 3 days) in 
10 patients with MDS and 4 of these patients achieved CR.21 
This and other studies exploring low-dose decitabine led to 
a larger Phase II trial by Wijermans and colleagues22 using a 
different dosing schedule of 15 mg/m2 infused over a 4-hour 
period every 8 hours (total of 45 mg/m2/day) for 3 consecu-
tive days every 6 weeks, in which results demonstrated an 
overall response rate (ORR = CR + PR) of 49% with a CR 
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of 20% and a PR of 4%. A pooled analysis of the Phase II 
studies from Europe has also been published.6 In this analy-
sis, 177 patients received decitabine 40 to 50 mg/m2/day for 
3 days every 6 weeks leading to an ORR of 49% with a CR 
of 24%, a PR of 10%, and an HI of 14%.
These encouraging results led to the landmark multi-
institutional Phase III trial in the United States where 
170 patients with de novo or t-MDS were randomized to 
receive decitabine plus supportive care versus supportive care 
alone.9 Decitabine was administered as a scheduled dose of 
15 mg/m2 every 8 hours intravenously daily for 3 days every 
6 weeks. The primary endpoints of the study were ORR 
and time to AML transformation or death. Best supportive 
care included blood transfusions for patients with hemoglo-
bin 8 g/dL, platelet transfusions for platelets 7.5 × 109/L, 
and administering hematopoietic colony-stimulating factors 
per study guidelines. Results of an intention to treat analysis 
of the total study population demonstrated that decitabine 
had a significantly better ORR as compared to patients on 
the supportive care arm (17% versus 0%, P  0.001), with 
a CR of 9% and a PR of 8%. Further, an HI was seen in 13% 
of patients on the decitabine arm compared to 7% of patients 
treated with supportive care (P  0.001). Further, although 
not statistically significant, patients treated with decitabine 
had a delay to AML transformation or death of 4.3 months 
(P = 0.16). In the subgroup analysis, patients who were 
treatment-naïve, had an Int-2/high-risk IPSS risk score, or had 
de novo MDS, benefitted the most. The study design limited 
the number of courses of decitabine since patients who main-
tained a CR for 2 cycles were removed from the therapy arm. 
Due to myelosuppressive side effects, 18 patients had their 
treatment interrupted. A median of 3 courses of decitabine 
was administered. Of the group receiving decitabine, 52% 
received greater or at least 3 courses and 26% received 
greater than 6 courses. Treatment with decitabine led to a 
trend of RBC transfusion-independence when compared 
to best supportive care. Statistically significant sustainable 
improvements in global health status, fatigue, and dyspnea 
were detected in patients treated with decitabine.9 Based on 
this pivotal study, the FDA approved decitabine in May of 
2006 for patients with for MDS (Int-1 or higher IPSS class) 
at the dose of 15 mg/m2 every 8 hours intravenously daily 
for 3 days every 6 weeks.
Long-term results of decitabine have not been com-
pared to chemotherapy in higher-risk MDS. Specifically, 
the survival advantage with treating patients diagnosed with 
higher-risk MDS with decitabine is unknown. Kantarjian 
et al’s subsequent single-center study comparing the efficacy 
and toxicity of decitabine to a historical control group treated 
with intensive chemotherapy in higher-risk MDS suggested a 
survival advantage associated with decitabine and prompted 
attention to the need for prospective analysis.23 This study 
analyzed the decitabine treatment arm to two historic inten-
sive chemotherapy groups, one that matched each patient 
receiving decitabine to a patient from the intensive chemo-
therapy group with similar age, chromosomal abnormalities, 
and IPSS risk group prior to treatment, and the other study 
group included the entire cohort of 376 identified historic 
patients treated with intensive chemotherapy. Results dem-
onstrated a statistically significant overall survival advantage 
of 22 months for those in the decitabine arm, compared to 
12 months in the first intensive chemotherapy group with 
matched characteristics, and a 2-year survival advantage 
of 47% versus 24% (P  0.001). In particular, patients 
greater than 60 years of age had a 2-year survival rate of 
40% versus 20% with decitabine (P = 0.001). In compari-
son to the second group of patients who received intensive 
chemotherapy, patients treated with decitabine demonstrated 
an overall survival advantage at 2 years with 47% versus 
21% (P  0.0001). Patients with poor prognostic factors 
of chromosome 5 or 7 abnormalities, thrombocytopenia, 
and older age did not have a statistically significant survival 
advantage with decitabine (P = 0.06). Despite the suggested 
survival advantage data from this historical comparison with 
decitabine, the CR rate was lower in this treatment arm.
Survival was again assessed as an endpoint in the follow-up 
randomized, multi-centered Phase III study of the EORTC 
Leukemia and German MDS Study Groups comparing overall 
survival with low dose decitabine versus supportive care in 
patients over 60 years old diagnosed with primary or second-
ary MDS or CMML.24 Those on the decitabine arm were given 
a treatment schedule of 15 mg/m2 intravenously over 4 hours 
every 8 hours for the first 3 consecutive days of every 6-week 
cycle, for a maximum of 8 cycles. Poor risk cytogenetic 
abnormalities were detected in 46% of the patients. Patients 
were given a median of 4 cycles of decitabine, with 40% of 
them getting no more than 2 cycles. Results of this trial dem-
onstrated an ORR of 34%. There was no significant difference 
in the decitabine versus supportive care arm regarding time to 
AML progression or death. Overall survival was lower and 
was not found to be statistically significant, likely due to the 
shorter treatment duration or to the subsequent therapy given, 
such as transplant or induction chemotherapy, to patients with 
disease progression.
The response rate from these decitabine studies has been 
modest, and by the time of these studies, the optimal dose OncoTargets and Therapy 2010:3 
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of decitabine was not yet determined. With the intent of 
achieving maximal efficacy and minimal toxicity, a single-
center randomized Phase II study was performed in which 
95 patients with either higher-risk MDS or CMML received 
1 of 3 schedules of low-dose decitabine.25 Randomized 
schedules included 20 mg/m2 intravenously daily for 5 days, 
20 mg/m2 subcutaneously daily for 5 days, and 10 mg/m2 
intravenously daily for 10 days. Results demonstrated that 
34% of patients in the study achieved CR, and 73% had an 
objective response according to the modified IWG criteria. 
In an attempt to correlate clinical activity of decitabine to 
its epigenetic activity in vivo, the authors studied global 
LINE1 methylation patterns and the level of p15 activation 
expressed in treated patients. Data from this study suggested 
that decitabine had in vivo hypomethylating activity. The 
superior clinical arm was associated with the most rapid and 
profound induction of hypomethylation as well as induction 
of p15INK4B. The authors concluded that a 5-day course of 
intravenous therapy at a dose of 20 mg/m2 daily was superior 
at inducing hypomethylation at day 5 and at activating p15 
expression at days 12 or 28 after therapy.25
In an update of these data, the authors reported a median 
survival of 22 months, with an estimated 2-year survival rate 
of 47%.26 Given the results of the optimal dosing schedule, 
an adaptive randomization strategy was used to select the 
regimen of 20 mg/m2 intravenously daily for 5 days, due to 
the associated higher CR rate in this and previous studies. 
Interestingly, patients required a median number of 7 courses 
to achieve CR. The CR rate was 35% with decitabine, and 
the ORR was 70%. In addition to these findings, the authors 
identified prognostic factors associated with response and 
survival. As determined by multivariate analysis, poor prog-
nostic factors identified for achieving CR as determined by 
IWG criteria included MDS versus CMML, longer history 
of MDS, and previous MDS therapy. Poor prognostic factors 
for survival included chromosome 5 and/or 7 abnormalities, 
older age, and previous MDS therapy. Despite the poor 
prognosis associated with chromosome 5 and 7 abnormali-
ties, Ravandi et al demonstrated improved overall survival 
with hypomethylating agents when compared to intensive 
chemotherapy for treatment of AML and high-risk MDS with 
those cytogenetic features.27 Results demonstrated that 41% 
of patients in the hypomethylating arm achieved CR versus 
35% of patients in the chemotherapy group (P = 0.395). 
Specifically, 56 patients were treated with decitabine alone 
and 23 achieved CR. Patients treated with a hypomethylating 
agent had a survival advantage when compared to those who 
received cytotoxic chemotherapy (P = 0.019). Hence, patients 
diagnosed with difficult to treat MDS, such as those with the 
poor prognostic factors, have been shown to benefit from 
decitabine when compared to intensive chemotherapy.
More recently, robust data collected from the Alter-
native Dosing for Outpatient Treatment (ADOPT) trial 
demonstrated clinical benefit of decitabine to patients with 
MDS. This multicenter, nonrandomized, and open-label trial 
tested the efficacy and safety of an outpatient regimen of 
20 mg/m2 of decitabine infused intravenously over 1 hour 
daily for 5 consecutive days every 4 weeks using ORR as the 
primary endpoint.28 Patients with a median age of 72 years 
were enrolled. Using IPSS risk scoring, study investigators 
identified 23% high, 23% Int-2, 53% Int-1, and 1% low-
risk persons among the group. The study design excluded 
dose escalations or reductions. Supportive care including 
transfusions was permitted and used according to physician 
discretion. For the 99 patients enrolled at 28 North American 
sites, the ORR was 32% (95% CI, 23% to 43%), and 18 of 
99 patients had HI (95% CI, 40% to 61%). The median 
time to initial clinical improvement was detected after the 
first 2 cycles, and the median duration of improvement was 
10 months. This study showed that 24% of patients required 
more than 5 cycles to achieve best response, further advo-
cating the need for repeated drug exposure over several 
cycles to achieve therapeutic benefit. Among the various 
IPSS risk groups in this study, clinical benefit was shown 
in 50% of those known to be intermediate-1, 61% of those 
identified as intermediate-2, and 43% for high-risk patients. 
There was an impressive rate of 73% improvement among 
CMML patients, defined as CR + mCR + PR + HI. Further, 
among the 33 patients with abnormal baseline cytogenetic 
analyses, there was a 52% cytogenetic response rate. Data 
collected from this study demonstrated a median survival of 
19.4 months by the closure of the study. The most common 
reported side effect was cytopenias. Studies prior to the 
ADOPT trial committed patients to frequent hospitaliza-
tions. Encouraging results from this study demonstrated that 
outpatient decitabine is comparable to the inpatient regimen 
tested in previous Phase III studies,9,24 and it affirmed the 
efficacy of the scheduling dose of 20 mg/m2 intravenously 
for 5 days every 4 weeks in Kantarjian’s single-center study23 
discussed above. This is now considered a standard outpatient 
regimen for decitabine.
In summary, the current trials of decitabine have shown 
modest clinical efficacy (ORR 17% to 32%) in patients 
with higher-risk MDS. Optimizing the dosing schedule 
of decitabine to maximize its hypomethylating effect 
includes using it at a low dose, at high dose intensity, and OncoTargets and Therapy 2010:3 
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in multiple cycles. Data demonstrating a survival advantage 
with the use of decitabine when compared to best supportive 
care have been analyzed only retrospectively.
Clinical efficacy in recurrent  
disease
For patients diagnosed with recurrent disease, decitabine 
remains a viable option given its low nonhematologic toxic-
ity profile, which allows for repeated courses. The studies 
above demonstrated that at least 3 courses of decitabine 
were needed to achieve efficacy. In an earlier study com-
bining 3 Phase II trials, the outcome of re-treatment with 
decitabine was studied in 22 high-risk MDS patients with 
low-dose decitabine at 15 mg/m2 over 4 hours given 3 times 
a day on 3 consecutive days for up to 6 to 8 courses at the 
time of disease recurrence.29 Sixty percent of these patients 
achieved a clinical response (CR, PR, or HI) after receiving 
a median of 6 courses of decitabine. Of the 65 patients who 
responded well to decitabine, 22 patients with recurrent 
disease demonstrated an inferior response upon subse-
quent exposure. The remaining 43 patients with recurrent 
disease were treated with induction chemotherapy or best 
supportive care, with or without low-dose chemotherapy. 
In 10 of the 22 patients with recurrent disease who were 
given re-treatment with decitabine, 7 patients achieved a HI, 
2 patients achieved a PR, and 1 patient achieved a second 
CR. The duration of this second response was 4 months, 
approximately 2.5 times shorter in duration than on the 
first response. Of the remaining 12 patients with recurrent 
disease who were offered decitabine again, resistance was 
evident in 4 patients. Altogether, 45% of patients receiving 
decitabine again were still treatment sensitive. Although the 
focus of this study was re-treatment effects and the potential 
of decitabine as maintenance therapy, the data strongly sug-
gest prolonging initial therapy.29
Outcomes in lower-risk MDS  
and CMML
Management of patients with lower risk MDS relies primar-
ily on supportive care and hematopoietic growth factors, 
particularly erythropoiesis-stimulating agents. Patients with 
5q- Syndrome are often treated with lenalidomide, which is 
considered standard of care.30 Decitabine is considered for 
patients with symptomatic anemia who fail to respond to 
agents like darbepoeitin or granulocyte colony-stimulating 
factor. Limited data are available demonstrating the clinical 
efficacy of decitabine in these diseases. However, given the 
risk of iron overload and its complications related to hepatic, 
cardiac, and endocrine function, as well as the potential need 
to treat with deferoxamine, decitabine represents a potential 
alternative and may obviate the degree of supportive care. 
A Phase II trial sponsored by the CALGB focused on the 
clinical efficacy of subcutaneous decitabine to adults with 
low or intermediate-1 risk MDS is ongoing (Clinicaltrials.gov 
Identifier NCT00619099), and may provide further insight 
on its efficacy in lower risk MDS.
CMML is an uncommon clonal disorder of the bone 
marrow that has been classified as a myelodysplastic/myelo-
proliferative (MDS/MPS) according to WHO classification 
given its heterogeneous clinical, hematological and mor-
phologic features.2 The median survival in CMML is 18 to 
20 months from diagnosis.31 Subset analysis on patients 
diagnosed with CMML from existing decitabine trials has 
offered invaluable insight on the management of a disease 
that is difficult to treat as there are few studies to date that 
study CMML alone. The experience with decitabine in 
CMML was demonstrated in three open-label and single-arm 
multicenter Phase II studies (PCH 91-1,32 PCH 95-11,22 PCH 
97-196) and a multicenter Phase III study (D-00079) retro-
spectively reviewed by Wijermans et al.33 Overall, results 
from those 4 studies demonstrated an ORR of 26% (10% 
CR + 16% PR), a HI of 19%, a median of 15-month survival 
from initial decitabine treatment (95% CI, 8 to 22 months), 
and a 2-year survival of 25%. In the trial conducted by 
Aribi et al to evaluate the activity of decitabine in patients 
diagnosed with CMML, 19 patients with CMML were given 
1 of 3 schedules of decitabine with total dose per course of 
100 mg/m2.34 The study design dictated repeated courses 
every 4 weeks for a minimum of 3 courses without dose 
escalations. Results demonstrated an ORR of 68%, a CR 
of 58%, a HI of 11%, and a 2-year survival rate of 48%. 
Patients were exposed to a median of 9 courses of decitabine. 
Larger randomized trials featuring patients with CMML are 
needed to further establish the potential of decitabine for this 
difficult to treat disease.
Future of decitabine with HCT
Most patients with intermediate and high-risk MDS are 
not candidates for allogeneic HCT because of their age 
and co-morbidities. It is not clear whether or not induction 
chemotherapy should be used routinely before undergoing 
HCT. The current 3-year survival rate of HCT in patients with 
less advanced MDS is 65% to 80% with human leukocyte 
antigen-identical related and unrelated donors, and 35%–50% 
in those with advanced MDS (defined as greater or equal to 
5% marrow blasts) from related donors versus 25% to 40% OncoTargets and Therapy 2010:3 
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from unrelated donors.35 Failure to benefit from HCT is likely 
due to treatment-related mortality or to relapse. Decreasing 
the toxicity or dose reduction of conditioning regimens has 
reduced the treatment-related mortality but has had a minimal 
effect on the risk of relapse.
Alternative regimens that can potentially alter the natural 
course of MDS include hypomethylating agents, histone-
deacetylase inhibitors, or lenalidomide.36 These agents have 
been used as mono-versus combination therapy to improve 
the pre-transplant remission status prior to HCT or have been 
given post-transplant to prevent relapse in the form of main-
tenance or consolidation therapy.37–40 In a study evaluating 
the outcomes of 17 patients with MDS who underwent an 
allogeneic HCT after previous exposure to decitabine, results 
did not demonstrate increased toxicity with decitabine.41 
Further, 100 days after transplant, 13 of 17 patients who 
underwent an allogeneic HCT were in CR, and 1 year later, 
11 of these 13 patients were alive with 8 patients in CR and 
3 patients with progressive disease. Several ongoing and 
planned clinical trials will also evaluate the role of decitabine 
as maintenance therapy after HCT.
Safety and tolerability
In the above described Phase II and Phase III trials, decitabine 
was generally safe and well tolerated. At its therapeutic dose, 
decitabine has favorable and manageable side effects, making 
it amenable to the elderly patient population in the treatment 
of MDS. Table 2 summarizes the toxicities seen in the studies 
discussed above using the NCI Common Toxicity Criteria 
for Adverse Events. The most common grade 1–2 adverse 
events reported included bleeding, fatigue, and nausea. Of the 
grade 3–4 side effects, the most frequent were neutropenia 
and thrombocytopenia. Given the myelosuppressive effects, 
it is recommended that patients continue antifungal and anti-
biotic prophylaxis while on decitabine.42 Cardiovascular and 
gastrointestinal abnormalities, in particular, are uncommon. 
The poorly tolerated cytotoxic side effects of mucositis, hair 
loss, diarrhea, and renal failure are uncommon with the use 
Table  reported adverse effects of decitabine
Adverse event Grade %–% affected Grade %–% affected Reference
Neutropenia 1 31, 86* 9, 28
Thrombocytopenia 2 18, 85* 9, 28
Anemia 5 12* 9, 28
Bleeding 46 7 25
Febrile neutropenia,  
fever of unknown origin
3 6, 14, 20, 23*, 33 6, 9, 25, 28, 34, 46
Leukopenia 22* 9
Pyrexia 6* 9
Liver dysfunction 2, 10, 11 1, 1, 4, 6* 6, 9, 25, 26, 34
Pneumonia 1 2, 11, 15*, 20 6, 9, 25, 28, 34
Nausea 2, 17, 26 0, 1*, 7 6, 9, 25, 26, 28, 34
Pyrexia 17 0 28
Constipation 11 0, 2* 9, 28
Chills 10 0 28
Diarrhea 1, 2, 12 0* 9, 25, 26, 28, 34
Abdominal pain 2* 9
Bone aches 0, 4, 10 2, 5 25, 26, 34
Skin rash 0, 1 0 25, 26, 34
Fatigue 1, 6, 26 0, 5 25, 28, 34
Cardiovascular 8 6
Mucositis 4 6
Anorexia 12 0, 1 6, 28
Sleep disorder 1 6
Alopecia 1 6
Anaphylactic reaction 1 6
Deafness 1 6
Headache 1 6
*Grade 3 and 4 data from the Phase iii Decitabine study9 were combined for the purposes of this review.OncoTargets and Therapy 2010:3 
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of decitabine. Other rare reported adverse events include 
pleural effusion and acute fibrinous and organizing pattern 
of lung injury.43,44
Toxicity data that probably most accurately reflect 
what would be expected across many treatment settings 
can be taken from randomized Phase II and Phase III 
studies of decitabine.9,28 For instance, in the Phase III 
study by Kantarjian et al. of the 83 patients treated with 
decitabine, 69% experienced severe side effects includ-
ing neutropenia, thrombocytopenia, febrile neutropenia, 
leucopenia, pyrexia, hyperbilirubinemia, and pneumonia.9 
Infrequent side effects included gastrointestinal toxici-
ties (5%). Decitabine dose reductions occurred in only 
35% of patients. In the ADOPT trial, cytopenias were the 
most common reported grade 3 adverse event at rates of 
31% for neutropenia, 18% for thrombocytopenia, 14% for 
febrile neutropenia, and 12% for anemia.28 Notably, febrile 
neutropenia occurred most commonly in the first cycle, in 
particular 10% of patients. Thirty-two percent of patients 
had delayed therapy mostly because of myelosuppression at 
a median of 8 days, and 19% of administered cycles were 
associated with a hospitalization. Typical dose reductions 
of 25%–30% were considered for grade 3 and 4 nonmyelo-
suppressive toxicities, severe myelosuppressive toxicities, 
or prolonged bone marrow suppression.25,26,34
From the collective experience with decitabine, several 
general principles emerge. To achieve a maximum therapeutic 
benefit, delivery of the next scheduled dose of decitabine 
should not be delayed, unless patients experience disease 
progression, febrile neutropenia, or profound cytopenias 
as evident by bone marrow examination (5% cellular). 
Results from studies to date demonstrate that the more com-
mon adverse effects are transient, nonfatal, and amenable to 
dose adjustment. Management of adverse effects especially 
myelosuppression is essential to prevent early discontinuation 
of decitabine therapy before achieving therapeutic benefit.
Clinical efficacy compared  
to 5-azacitidine
In addition to decitabine, 5-azacitidine is the other FDA-
approved hypomethylating agent that has become widely 
used to treat patients with MDS. The clinical benefits of 
5-azacitidine were best demonstrated in the randomized, 
open-label, landmark Phase III study, which demonstrated 
better survival than with best conventional care, including 
chemotherapy.45 In this study, 358 patients with higher-risk 
MDS were randomized to 5-azacitidine or conventional 
care, which included best supportive care with transfusion 
products and granulocyte-colony-stimulating factor for 
neutropenic fever, low-dose cytarabine, or intensive 
chemotherapy with primary outcome of overall survival. 
Interestingly, after a median follow up of 21.1 months, 
patients in the 5-azacitidine arm of the study had a median 
of 24.5 months overall survival compared to 15 months 
for patients treated with conventional care (stratified log-
rank P = 0.0001). At 2 years follow-up, 50.8% of patients 
on 5-azacitidine were still alive compared to 26.2% in the 
conventional care arm (P  0.0001). Subgroup analysis 
demonstrated a statistically significant overall survival 
benefit with 5-azacitidine when compared to best supportive 
care or cytarabine. Statistical significance was not reached 
when comparing the study drug to intensive chemotherapy. 
Secondary endpoints included hematological response, 
transfusion independence, and hematological improvement. 
When compared to best supportive care, there was a clear 
advantage of 5-azacitidine to prolonging transformation 
to AML by 6 months. Findings of this study suggest long-
term treatment with at least 6, and even up to 9, cycles of 
5-azacitidine may confer the best survival benefit. It remains 
unknown whether patients with an excess of marrow blasts 
or unfavorable karyotype would benefit from 5-azacitidine 
before transplantation.
A common clinical dilemma faced by clinicians is 
whether one hypomethylating agent provides benefit after 
a patient fails the other FDA-approved agent. This question 
has been addressed by a Phase II trial, in which sequential 
treatment with decitabine in 14 patients with MDS who 
failed 5-azacitidine was studied.46 Early analysis of this 
Phase II trial looked at the effect of decitabine on the ORR 
of 14 patients who had MDS and either 5-azacitidine fail-
ure, lack of response, or intolerance. Results showed that 
3 patients achieved CR and 1 patient had a marrow CR with 
HI, leading to an ORR of 28%.
Clinical trials have not yet compared the treatment 
advantage of decitabine directly to 5-azacitidine. Although 
decitabine has shown equal if not better efficacy than 
azacitidine, there are no prospective data showing increased 
survival. In the single-center historical study23 comparing the 
outcome of patients with higher-risk MDS when treated with 
decitabine versus intensive chemotherapy, results suggested 
a survival advantage for those treated with decitabine (47% 
versus 24%, P  0.001). In contrast, 5-azacitidine has been 
shown to have a statistically significant survival advantage 
(2-year survival, 50.8% versus 26.2%, P  0.0001) when 
compared to best conventional care in a large, randomized, 
controlled, multicenter Phase III study.45OncoTargets and Therapy 2010:3 0
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Further, without a randomized comparison of decitabine 
and 5-azacitidine, selection of the optimal hypomethylating 
agent for patients diagnosed with MDS remains a challenge 
for clinicians. Until data from a head-to-head trial are avail-
able, two stimulating studies have been published that have 
generated further interest in the use of hypomethylating 
agents. In the first study, Gurion et al generated a systematic 
review and meta-analysis of randomized controlled trials 
(RCTs) comparing treatment with hypomethylating agents 
to conventional care in MDS patients. This study suggests 
5-azacitidine was superior to decitabine in the treatment of 
MDS.47 The authors analyzed the efficacy of hypomethylat-
ing agents versus supportive care for patients with MDS in 
4 RCTs that included 952 patients a median age between 
67 and 70 years. Results demonstrated a statistically sig-
nificant overall survival (HR 0.66, 95% CI 0.55 to 0.80), 
and, in particular, an advantage for 5-azacitidine (HR 0.56, 
95% CI 0.44 to 0.73). A survival benefit could not be shown 
for decitabine (HR 0.88, 95% CI 0.66 to 1.17). Compared 
to conventional care, hypomethylating agents slowed pro-
gression to AML or death (HR 0.69, 95% CI 0.58 to 0.82). 
Individually, 5-azacitidine clearly had an advantage when 
compared to conventional care (HR 0.59, 95% CI 0.42 to 
0.70) versus decitabine (HR 0.85, 95% CI 1.41 to 41.17). 
Surprisingly, treatment-related mortality was associated with 
hypomethylating agents (RR 7.27, 95% CI 1.67 to 31.67). It 
is possible that the decitabine data were not as robust given 
the low median number of courses of treatment offered, since 
previous studies have demonstrated clinical benefits with at 
least 6 cycles of therapy.
In a second meta-analysis, Kumar et al compared 
decitabine and 5-azacitidine in the treatment of MDS using 
the same RCTs, and their results also uphold the suggested 
5-azacitidine superiority to decitabine.48 In the follow-up letter 
to the editor, Kumar et al further highlighted the differences 
between the two meta-analyses, including the addition of sur-
vival data from the Phase III randomized study by Kantarjian 
et al and the determination of a clinically nonsignificant differ-
ence between 5-azacitidine and supportive care in the study by 
Silverman et al.9,49,50 Their analysis led to the conclusion that 
there was no statistically significant overall survival advan-
tage with the use of hypomethylating agents in comparison 
to supportive care. Similar to the analysis by Gurion et al, 
pooled data for 5-azacitidine showed similar overall survival 
advantage (0.62, 95% CI 0.48 to 0.78, P = 0.030). Kumar et al 
further demonstrated no survival advantage with decitabine 
(0.98, 95% CI 0.81 to 1.18, P = 0.815). Also, no statistically 
significant treatment-related mortality was found. Using an 
adjusted indirect comparison of the two hypomethylating 
agents, Kumar et al demonstrated a statistically significant 
survival advantage with 5-azacitidine.
A direct comparison between decitabine and 5-azacitidine 
is currently underway. Recently, Eisai Corporation of North 
America initiated a randomized, multicenter, open label 
study designed as a head-to-head noninferiority trial to test 
if decitabine is equivalent to 5-azacitidine in the treatment 
of patients diagnosed with MDS (Clinicaltrials.gov Identifier 
NCT01011283). The study plans to enroll 228 adults with 
Int-1, Int-2, and high-risk MDS who will be randomized to 
either decitabine or 5-azacitidine. The primary objective is 
to compare complete response rates, including bone marrow 
response rates. Results from this trial are eagerly awaited 
and may highlight the clinical differences between these two 
hypomethylating agents.
Synergy with other agents in MDS
Given the fact that clinical efficacy for single agent decitabine 
in MDS and AML is at best considered moderate with rela-
tively low CR and PR rates (20% to 35%), there is a need to 
develop effective combination therapies aimed at improv-
ing the response rates, response duration, and eventually 
survival in these patients. Epigenetic modulation, such as 
DNA methylation and histone deacetylation can cause reac-
tivation of silenced genes, and in combination, these agents 
may work better than they can individually. The rationale 
for this combination emerged from studies demonstrating 
synergistic effects in the reactivation of epigenetically 
silenced genes.14,51,52 In particular, 5-azacitidine and sodium 
phenylbutyrate, an HDACi, were used in combination in 
the Phase I study focused on the treatment of patients diag-
nosed with MDS and AML, which demonstrated reversal 
of aberrant epigenetic gene silencing.14 Clinical outcomes 
demonstrated 5 major responders (4 patients with CR and 1 
patient with PR) out of 29 evaluable patients in this study. 
DNA methylation in bone marrow cells was examined by 
genomic bisulfite sequencing of a hypermethylated p15 
promoter. Results from sequential sequencing of DNA in 
patients who demonstrated PR, CR and HI demonstrated 
both a significant decrease in p15 methylation following 
the administration of 5-azacitidine and a pattern of hetero-
geneous loss of CpG methylation, suggesting demethylation 
within the tumor clone. Interestingly, 5-azacitidine alone or 
in combination with phenylbutyrate led to increased histone 
acetylation in 17 of 23 patients. Larger studies are needed to 
evaluate the clinical efficacy of combining DNMT therapy 
with HDACi in the treatment of MDS.OncoTargets and Therapy 2010:3 
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Combination therapy of decitabine and valproic acid 
(VPA, an HDACi) is a well-studied combination. Garcia-
Manero et al evaluated the safety and activity of this combi-
nation in a Phase I–II study in 54 elderly patients with MDS 
and AML.53 Based on their preclinical data,54 a concomitant 
dosing schedule was used. The dose of decitabine was 
15 mg/m2 intravenously daily for 10 days. In the Phase 1 
portion of the study, 3 dose levels of VPA were studied (20, 
35 and 50 mg/kg orally daily for 10 days) and 50 mg/kg daily 
was established as maximal tolerated dose (MTD). Of the 
32 patients treated at 50 mg/kg daily VPA dose, 9 developed 
grade 3 nonhematological toxicity, mainly neurotoxicity. 
Overall, CR was documented in 22% of the patients. The 
median time to response was 2 months, and the median 
response duration was 7.2 months. In the subgroup analysis, 
50% CR + CRp (CR with incomplete platelet recovery) was 
noted in 10 previously untreated patients. Higher VPA lev-
els were associated with higher nonhematological toxicity; 
however no correlation between VPA levels and response 
was observed.
In the subgroup analysis restricted to previously untreated 
patients (n = 10), a 50% CR + CRp (CR with incomplete 
platelet recovery) was noted, and the responders had signifi-
cantly higher free VPA levels at day 10 compared to nonre-
sponders (32.4 mg/L versus 14.0 mg/L, P = 0.03). Histone 
H3 and H4 acetylation was documented in 35% of patients at 
50 mg/kg VPA dose. However, no correlation was observed 
between induction of hypomethylation or histone acetylation 
and clinical response.
Blum et al conducted a Phase I study using decitabine 
alone or in combination with VPA in patients with AML.13 
Twenty-five patients were treated with decitabine dosed at 
20 mg/m2 daily IV for 10 days as the optimum biologic dose. 
VPA was added in escalating doses (15, 20, 25 mg/kg orally 
daily) for days 5 to 21, and the MTD for the combination 
therapy was 20 mg/kg daily. A CR plus CRi (CR with incom-
plete count recovery) was noted in 8 patients. There was 
no difference in the p15 or ER expression levels in patients 
who received combined therapy versus those who received 
decitabine at 20 mg/m2 dosing. The authors concluded that 
the clinical impact of adding VPA to decitabine in this study 
remained unclear.
Decitabine has also been combined with suberoyl-
anilide hydroxamic acid (SAHA, vorinostat, another 
HDAC inhibitor). In the preliminary results of a Phase I 
study reported by Ravandi et al, 5 cohorts of 6 patients 
each received escalating doses of decitabine (10, 10, 15, 20 
and 25 mg/m2 intravenously daily for 5 days) followed by 
vorinostat (100 mg orally 3 times a day for 14 days in the 
first cohort and 200 mg orally 3 times a day for 14 days in 
subsequent cohorts).55 Two-thirds of the patients had refrac-
tory AML. Of the 30 evaluable patients, 1 patient achieved 
CR, and 4 had significant reduction in the bone marrow blasts. 
Correlative studies have not been reported for this study.
Conclusions
The emergence of new treatments for MDS especially hypo-
methylating agents has generated enthusiasm about a new era 
of management beyond poorly tolerated cytotoxic therapies 
and best supportive care. Decitabine has been evaluated 
primarily in adults diagnosed with higher risk MDS. The 
potential role of decitabine as a first-line option in patients 
diagnosed with MDS who are candidates for allogeneic HCT 
has not been extensively evaluated and presents an oppor-
tunity for future research and development. The field also 
eagerly awaits the results of additional translational studies 
focusing on decitabine alone or in synergy with other agents 
to understand its mechanism of action and activity in MDS 
further. Decitabine has not shown statistically significant 
evidence of prolonged survival benefits in prospective trials 
to date, and how its efficacy compares to 5-azacitidine is not 
yet known. We look forward to the results of the head-to-head 
randomized trial of decitabine and 5-azacitidine to provide 
us with further guidance in the management of patients with 
higher risk MDS.
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